←
Carl June65 posts
Carl June avatar

Carl June

@carlhjune
◷ Joined December 2014▧ 8 Photos and videos
Daniel Baker avatar
⟳ Carl June retweeted
Daniel Baker@daniel_baker_j·Jun 30

Can AI help identify targets for living therapies? We grounded frontier LLMs with patient tumor data and public knowledge bases, then tested their ability to nominate targets. GPNMB rose to the top—and GPNMB CAR T cells showed promise across blood and solid-tumor models.

Post attachment

In the latest issue! AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy dlvr.it/TTHFjJ

Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 avatar
⟳ Carl June retweeted
Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉@BLLPHD·Apr 29

Heading to the @ISCTglobal Annual Meeting in Dublin? Come visit us at the Penn Medicine Clinical Cell and Vaccine Production booth 2505 1st Floor The Liffey across from ISCT Hub and meet our Facilities, Analytics, Operations, Regulatory and Manufacturing Experts. We’ve built an integrated platform designed to move programs from discovery into first-in-human studies with rigor, speed, and quality. What differentiates this model is not a single capability, but the integration: • cGMP Phase I manufacturing in 15 ISO 7 suites • Process development and scale-up for complex cell therapies • End-to-end QC analytics and FACT-aligned quality systems • Advanced correlative science, including multiparameter flow, molecular assays, and spatial biology • Deep experience translating across oncology and immune diseases We are actively looking to partner with biotech, pharma, and academic groups in three areas: • Manufacturing: early-phase and first-in-human CGT production • Process development: improving robustness, scalability, and comparability • Analytics and correlative studies: biomarker strategies that inform mechanism, response, and durability If you are advancing a program and need a partner who understands both the science and the realities of clinical translation, we should connect to build the next generation of cell and gene therapy together. #celltherapy #genetherapy #innovation #immunotherapy

Post attachment
Ugur Uslu avatar
⟳ Carl June retweeted
Ugur Uslu@UgiUslu·10 May 2024

Check out our latest paper, published @NatureComms. We show that STING activation induces IL18 secretion and thereby enhances CAR T function. Great collaboration between @CarlHJune lab and James Chen @UTSWMedCenter. @PennMedicine @PennMDForum @PennPPA nature.com/articles/s41467-0…

Carl June avatar
Carl June@carlhjune·30 Apr 2024

wonderful work from @sonia guedan, former post doc. From her lab in Barcelona,j ust published in Nature Communications doi.org/10.1038/s41467-024-4…

Carl June avatar
Carl June@carlhjune·9 Feb 2024

Anti-competitive practices of 10X genomics have forced Nanostring into chapter 11 restructuring. 10x has initiated litigation against not only Nanostring but also Vizgen, Curio Biosciences and Parse Biosciences. See below for more information: (genengnews.com/topics/bioper…) (genengnews.com/topics/omics/…)

Carl June avatar
Carl June@carlhjune·24 Jan 2024

x.com/sixers/status/17499155… My lab in Spotlight at 76ers historic game when Embiid scored 70 points and set a franchise record for the 76ers. @PennMedicine

🩺 @PennMedicine spotlight: last night we recognized Dr. Carl June, the Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. Dr. June is joined by members of the June Laboratory, which provides researchers with the tools they need to translate laboratory insights into safe and effective cancer therapies. The June Lab has many faculty researchers focused on developing ways to enhance the ability of the natural immune system to recognize and eliminate tumor cells.

Post attachment
Stephan Grupp MD PhD avatar
⟳ Carl June retweeted
Stephan Grupp MD PhD@GruppSteve·10 May 2022

10 years ago Emily Whitehead’s family got the news that she was cancer free. We wondered whether these #carTcells could keep her in remission and cure her disease without BMT. Now we know. 10 years from this transformative clinical experience, 5 years from @FDA approval.

Today, Emily is 10 years cancer free! With this important milestone reached, we can now also celebrate that Emily is CURED. https://t.co/Vodpc7n1qa #WeBelieve #ActivateTheCURE #10YearsofCART

Post attachment
Carl June avatar
Carl June@carlhjune·22 Feb 2022

The June lab is excited to offer a postdoctoral position with a focus on T cell engineering and synthetic biology in the Center for Cellular Immunotherapies at the Perelman School of Medicine at the University of Pennsylvania.

Carl June avatar
Carl June@carlhjune·2 Feb 2022

Penn Patients with Decade-Long Leukemia Remissions after CAR T Cell Therapy Reveals New Details About Persistence of Personalized “Living Drug” Cells. Delighted to announce our study in Nature today

Carl June avatar
Carl June@carlhjune·7 Sep 2021

brave scientists against Texas Bravo Tom Curran and Myles Brown: Two members of the highest-level review board of the Cancer Prevention and Research Institute of Texas have submitted their resignations from the board of the state-funded institute.